Drilldown: Medicines

Pharmacopedia is being built in public. Pages may be incomplete.About this site

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Sedative-hypnotic

or [[:Category:Potassium_supplements|Potassium supplement]]

Use the filters below to narrow your results.

None (9)

None (3) · AMPA receptor antagonist (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (16) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA positive allosteric modulator; very long half-life (1) · GABAA potentiator (1) · GABAA potentiator and direct activator (3) · GABAB agonist; GHB receptor agonist (1) · Irreversible GABA-T inhibitor (1) · Melatonin receptor agonist (2) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Positive allosteric modulator of the GABAA receptor at the benzodiazepine binding site; increases frequency of Cl− channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) · Prodrug of phenytoin; sodium channel blocker (1) · Selective GABAA agonist (extrasynaptic delta subunit) (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1)

None (48) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-000002EE-QINU`"', '"`UNIQ--vote-000002EF-QINU`"' (1)

None (48) · 10-20 mEq PO daily for prevention; treat established hypokalemia per measured deficit, typically 40-100 mEq/d in divided doses; IV 10 mEq/h peripheral, 20 mEq/h central with telemetry (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (48) · 8, 10, 20, 25 mEq tablets/capsules (most ER); effervescent and oral solution; IV concentrate (must be diluted) (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)

None (48) · IV peripheral 10 mEq/h (40 mEq/L); IV central 20 mEq/h with cardiac monitoring; PO single doses generally ≤40 mEq (1) · N/A (never approved) (1)

None (48) · intranasal; rectal and IV reported. (1) · IV (1) · Oral (2) · sublingual (1)

None (48) · Hours (PO); IV faster but rate-limited (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (48) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · Variable; depends on ongoing losses (1)

None (48) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · Not meaningfully described for an electrolyte; distribution between intra- and extracellular compartments is the relevant kinetic (1)

None (48) · 60-80% (oral) (1) · Not formally characterized in humans. (1)

None (48) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Generally safe at replacement doses; treat the underlying cause of hypokalemia.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (49) · [[USLegal:Prescription only|Rx-only]] (higher concentrations and IV) and OTC (low-dose supplements) in US (1)

B

C

D

E

F

G

L

M

N

P

Q

R

S

T

V

Z